{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:53:42Z","timestamp":1792760022841,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10928-021-09761-0","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T14:02:41Z","timestamp":1621087361000},"page":"639-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-1594","authenticated-orcid":false,"given":"Michael","family":"Monine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Nestorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"key":"9761_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.05.009","volume":"144","author":"P Calias","year":"2014","unstructured":"Calias P, Banks WA, Begley D, Scarpa M, Dickson P (2014) Intrathecal delivery of protein therapeutics to the brain. Pharm Ther 144:114\u2013122","journal-title":"Pharm Ther"},{"key":"9761_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2165\/00003088-200140120-00003","volume":"40","author":"RG Thorne","year":"2001","unstructured":"Thorne RG, Frey WH (2001) Delivery of neurotropic factors to the central nervous system. Pharmacokinetic considerations. Clin Pharmacokinet 40:907\u2013946","journal-title":"Clin Pharmacokinet"},{"key":"9761_CR3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/00000542-200003000-00018","volume":"92","author":"WC Ummenhofer","year":"2000","unstructured":"Ummenhofer WC, Arends RH, Shen DD, Bernards CM (2000) Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanyl. Anesthesiology 92:739\u2013753","journal-title":"Anesthesiology"},{"key":"9761_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM (2016) Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86:890\u2013897","journal-title":"Neurology"},{"key":"9761_CR5","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, Norris DA, Xia S, Bennett CF, Bishop KM (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388:3017\u20133026","journal-title":"Lancet"},{"key":"9761_CR6","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM (2019) Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med 380:2307\u20132316","journal-title":"N Engl J Med"},{"key":"9761_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZH, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"9761_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA (2020) Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383:109\u2013119","journal-title":"N Engl J Med"},{"key":"9761_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP (2020) Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping. a phase 2 randomized clinical trial. JAMA Neurol 77:1\u201310","journal-title":"JAMA Neurol"},{"key":"9761_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","volume":"42","author":"CF Bennett","year":"2019","unstructured":"Bennett CF, Krainer AR, Cleveland DW (2019) Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci 42:385\u2013406","journal-title":"Annu Rev Neurosci"},{"key":"9761_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351","journal-title":"Adv Drug Deliv Rev"},{"key":"9761_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/nat.2017.0709","volume":"28","author":"CM Miller","year":"2018","unstructured":"Miller CM, Tanowitz M, Donner AJ, Prakash TP, Swayze EE, Harris EN, Seth PP (2018) Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver. Nucleic Acid Ther 28:119\u2013127","journal-title":"Nucleic Acid Ther"},{"key":"9761_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/jpet.113.212407","volume":"350","author":"F Rigo","year":"2014","unstructured":"Rigo F, Chun SJ, Norris DA, Hung G, Lee S, Matson J, Fey RA, Gaus H, Hua Y, Grundy JS, Krainer AR, Henry SP, Bennett CF (2014) Pharmacology of a central nervous system delivered 2\u2019-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J of Pharmacol Exp Ther 350:46\u201355","journal-title":"J of Pharmacol Exp Ther"},{"key":"9761_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12:435\u2013442","journal-title":"Lancet Neurol"},{"key":"9761_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers MM, Toonen LJA, van Roon-Mom WMC (2015) Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 87:90\u2013103","journal-title":"Adv Drug Deliv Rev"},{"key":"9761_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","volume":"13","author":"WM Pardridge","year":"2016","unstructured":"Pardridge WM (2016) CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv 13:963\u2013975","journal-title":"Expert Opin Drug Deliv"},{"key":"9761_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1213\/ANE.0b013e3182536211","volume":"115","author":"Y Hsu","year":"2012","unstructured":"Hsu Y, Madhawa Hettiarachchi HD, Zhu DC, Linninger AA (2012) The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth Analg 115:386\u2013394","journal-title":"Anesth Analg"},{"key":"9761_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1600-0404.1968.tb05563.x","volume":"44","author":"L Laitinen","year":"1968","unstructured":"Laitinen L (1968) Origin of arterial pulsation of cerebrospinal fluid. Acta Neurol Scand 44:168\u2013176","journal-title":"Acta Neurol Scand"},{"key":"9761_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/00000542-200402000-00021","volume":"100","author":"JL Krupp","year":"2004","unstructured":"Krupp JL, Bernards CM (2004) Pharmacokinetics of intrathecal oligodeoxynucleotides. Anesthesiology 100:315\u2013322","journal-title":"Anesthesiology"},{"key":"9761_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/psp4.12323","volume":"7","author":"K Biliouris","year":"2018","unstructured":"Biliouris K, Gaitonde P, Yin W, Norris DA, Wang Y, Henry S, Fey R, Nestorov I, Schmidt S, Rogge M, Lesko LJ, Trame MN (2018) A semi-mechanistic population pharmacokinetic model of nusinersen: an antisense oligonucleotide for the treatment of spinal muscular atrophy. CPT Pharmacometrics Syst Pharmacol 7:581\u2013592","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9761_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/jcph.884","volume":"57","author":"KT Luu","year":"2017","unstructured":"Luu KT, Norris DA, Gunawan R, Henry S, Geary R, Wang YJ (2017) Population pharmacokinetics of nusinersen in the cerebral spinal fluid and plasma of pediatric patients with spinal muscular atrophy following intrathecal administrations. Clin Pharmacol 57:1031\u20131041","journal-title":"Clin Pharmacol"},{"key":"9761_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1517\/17425255.3.2.235","volume":"3","author":"I Nestorov","year":"2007","unstructured":"Nestorov I (2007) Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235\u2013249","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"9761_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/psp4.12250","volume":"6","author":"Y Yamamoto","year":"2017","unstructured":"Yamamoto Y, V\u00e4litalo PA, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, van den Berg DJ, Hartman R, Wong YC, Danhof M, van Hasselt JGC, de Lange ECM (2017) Predicting drug concentration-time profiles in multiple CNS compartments using a comprehensive physiologically-based pharmacokinetic model. CPT Pharmacometrics Syst Pharmacol 6:765\u2013777","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9761_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/108729001750072092","volume":"11","author":"B Peng","year":"2001","unstructured":"Peng B, Andrews J, Nestorov I, Brennan B, Nicklin P, Rowland M (2001) Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Dev 11:15\u201327","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"9761_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10928-019-09641-8","volume":"46","author":"HY Chang","year":"2019","unstructured":"Chang HY, Wu S, Meno-Tetang G, Shah DK (2019) A translational platform PBPK model for antibody disposition in the brain. J Pharmacokinet Pharmacodyn 46:319\u2013338","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9761_CR26","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1124\/dmd.106.012401","volume":"35","author":"RZ Yu","year":"2007","unstructured":"Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35:460\u2013468","journal-title":"Drug Metab Dispos"},{"key":"9761_CR27","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/mtna.2014.69","volume":"4","author":"RZ Yu","year":"2015","unstructured":"Yu RZ, Grundy JS, Henry SP, Kim TW, Norris DA, Burkey J, Wang Y, Vick A, Geary RS (2015) Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2\u2019-o-(2-methoxyethyl) modifications. Mol Ther Nucleic Acids 4:e218","journal-title":"Mol Ther Nucleic Acids"},{"key":"9761_CR28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/mds.27782","volume":"34","author":"DR Scoles","year":"2019","unstructured":"Scoles DR, Pulst SM (2019) Antisense therapies for movement disorders. Mov Disord 34:1112\u20131119","journal-title":"Mov Disord"},{"key":"9761_CR29","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/0192623311436180","volume":"40","author":"ID Pardo","year":"2012","unstructured":"Pardo ID, Garman RH, Weber K, Bobrowski WF, Hardisty JF, Morton D (2012) Technical guide for nervous system sampling of the cynomolgus monkey for general toxicity studies. Toxicol Pathol 40:624\u2013636","journal-title":"Toxicol Pathol"},{"key":"9761_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ar.22847","volume":"297","author":"K Sakamoto","year":"2014","unstructured":"Sakamoto K, Sawada K, Fukunishi K, Noritaka I, Sakata-Haga H, Yoshihiro F (2014) Postnatal change in sulcal length asymmetry in cerebrum of cynomolgus monkeys (Macaca fascicularis). Anat Rec 297:200\u2013207","journal-title":"Anat Rec"},{"key":"9761_CR31","first-page":"33","volume":"40","author":"N Ageyama","year":"2001","unstructured":"Ageyama N, Shibata H, Narita H, Hanari K, Kohno A, Ono F, Yoshikawa Y, Terao K (2001) Specific gravity of whole blood in cynomolgus monkeys (Macaca fascicularis), squirrel monkeys (Saimiri sciureus), and tamarins (Saguinus labiatus) and total blood volume in cynomolgus monkeys. Contemp Topics Lab Anim Sci\/Am Assoc Lab Anim Sci 40:33\u201335","journal-title":"Contemp Topics Lab Anim Sci\/Am Assoc Lab Anim Sci"},{"key":"9761_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1124\/dmd.31.11.1419","volume":"31","author":"RS Geary","year":"2003","unstructured":"Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA (2003) Pharmacokinetics of a tumor necrosis factor-\u03b1 phosphorothioate 2\u2032-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31:1419\u20131428","journal-title":"Drug Metab Dispos"},{"key":"9761_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1006\/abio.2002.5576","volume":"304","author":"RZ Yu","year":"2002","unstructured":"Yu RZ, Baer B, Chappel A, Geary RS, Chueng E, Levin AA (2002) Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304:19\u201325","journal-title":"Anal Biochem"},{"key":"9761_CR34","first-page":"195","volume":"7","author":"RZ Yu","year":"2004","unstructured":"Yu RZ, Geary RS, Levin AA (2004) Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic\/pharmacodynamic assessment of antisense oligonucleotides. Curr Opin Drug Discov Devel 7:195\u2013203","journal-title":"Curr Opin Drug Discov Devel"},{"key":"9761_CR35","volume-title":"ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"DZ D\u2019Argenio","year":"2009","unstructured":"D\u2019Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles"},{"key":"9761_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1148\/radiology.157.2.4048444","volume":"157","author":"G Di Chiro","year":"1985","unstructured":"Di Chiro G, Knop RH, Girton ME, Dwyer AJ, Doppman JL, Patronas NJ, Gansow OA, Brechbiel MW, Brooks RA (1985) MR cisternography and myelography with Gd-DTPA in monkeys. Radiology 157:373\u2013377","journal-title":"Radiology"},{"key":"9761_CR37","first-page":"79","volume":"34","author":"F Sultan","year":"1993","unstructured":"Sultan F, Braitenberg V (1993) Shapes and sizes of different mammalian cerebella. A study in quantitative comparative neuroanatomy. J Hirnforsch 34:79\u201392","journal-title":"J Hirnforsch"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-021-09761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-021-09761-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-021-09761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T13:24:34Z","timestamp":1630329874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-021-09761-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["9761"],"URL":"https:\/\/doi.org\/10.1007\/s10928-021-09761-0","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]},"assertion":[{"value":"20 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}